X

Trial Profile

A PHASE 2 CLINICAL STUDY OF POMALIDOMIDE (CC-4047) MONOTHERAPY FOR CHILDREN AND YOUNG ADULTS WITH RECURRENT OR PROGRESSIVE PRIMARY BRAIN TUMORS

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pomalidomide (Primary)
Indications Brain cancer; Diffuse intrinsic pontine glioma; Ependymoma; Glioma; Medulloblastoma; Neurofibromatosis 1; Oligodendroglioma
Focus Therapeutic Use
Sponsors Celgene Corporation

Most Recent Events

05 Oct 2023 Status changed from active, no longer recruiting to completed.
31 Aug 2022 Planned End Date changed from 18 Mar 2023 to 27 Sep 2023.
15 Mar 2021 This trial has been completed in France, according to Eudra record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com